Feb 23, 2021
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development
Feb 04, 2021
UCB Community Health Fund supports Seven U.S. organizations on COVID-19 support projects
Dec 01, 2020
Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics
Nov 30, 2020
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Oct 07, 2020
UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts
Sep 22, 2020
UCB Achieves Important Regulatory Milestone for Bimekizumab
Jul 29, 2020
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Jul 27, 2020
UCB Half Year Report 2020
Jun 16, 2020
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
Jun 05, 2020
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Apr 10, 2020
UCB's General Meeting of Shareholders
Apr 02, 2020
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Apr 01, 2020
ADVANZ PHARMA Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million
Mar 06, 2020
ADVANZ PHARMA Corp. Limited Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products From UCB S.A. For Approximately $84 Million
Feb 25, 2020
Neuraxpharm Reinforces Presence in Poland
Feb 20, 2020
UCB Full Year Report 2019
Dec 12, 2019
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Dec 09, 2019
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Dec 05, 2019
UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
Oct 17, 2019
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab